These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 19466429)

  • 21. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High PSA and total prostatectomy: specific and overall 10-year survival].
    Paul A; Fourmarier M; Cordonnier C; Petit J; Petit J; Saint F
    Prog Urol; 2008 May; 18(5):299-303. PubMed ID: 18538275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life and satisfaction with outcome among prostate-cancer survivors.
    Sanda MG; Dunn RL; Michalski J; Sandler HM; Northouse L; Hembroff L; Lin X; Greenfield TK; Litwin MS; Saigal CS; Mahadevan A; Klein E; Kibel A; Pisters LL; Kuban D; Kaplan I; Wood D; Ciezki J; Shah N; Wei JT
    N Engl J Med; 2008 Mar; 358(12):1250-61. PubMed ID: 18354103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Blute ML
    J Urol; 2008 Apr; 179(4):1354-60; discussion 1360-1. PubMed ID: 18289596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer statistics, 2008.
    Jemal A; Siegel R; Ward E; Hao Y; Xu J; Murray T; Thun MJ
    CA Cancer J Clin; 2008; 58(2):71-96. PubMed ID: 18287387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of prostate weight on the outcomes of laparoscopic radical prostatectomy.
    Frota R; Turna B; Santos BM; Lin YC; Gill IS; Aron M
    BJU Int; 2008 Mar; 101(5):589-93. PubMed ID: 17922860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results.
    Bloch BN; Furman-Haran E; Helbich TH; Lenkinski RE; Degani H; Kratzik C; Susani M; Haitel A; Jaromi S; Ngo L; Rofsky NM
    Radiology; 2007 Oct; 245(1):176-85. PubMed ID: 17717328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
    Zwergel U; Suttmann H; Schroeder T; Siemer S; Wullich B; Kamradt J; Lehmann J; Stoeckle M
    Eur Urol; 2007 Oct; 52(4):1058-65. PubMed ID: 17418938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL.
    Gallina A; Jeldres C; Chun FK; Shariat SF; Briganti A; Walz J; Roehrborn CG; Saad F; Huland H; Graefen M; Montorsi F; Karakiewicz PI
    Eur Urol; 2007 Nov; 52(5):1374-80. PubMed ID: 17174466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
    Villers A; Puech P; Mouton D; Leroy X; Ballereau C; Lemaitre L
    J Urol; 2006 Dec; 176(6 Pt 1):2432-7. PubMed ID: 17085122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
    Stephenson AJ; Scardino PT; Eastham JA; Bianco FJ; Dotan ZA; Fearn PA; Kattan MW
    J Natl Cancer Inst; 2006 May; 98(10):715-7. PubMed ID: 16705126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
    Freedland SJ; Mangold LA; Walsh PC; Partin AW
    J Urol; 2005 Oct; 174(4 Pt 1):1276-81; discussion 1281; author reply 1281. PubMed ID: 16145392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical prostatectomy versus watchful waiting in early prostate cancer.
    Bill-Axelson A; Holmberg L; Ruutu M; Häggman M; Andersson SO; Bratell S; Spångberg A; Busch C; Nordling S; Garmo H; Palmgren J; Adami HO; Norlén BJ; Johansson JE;
    N Engl J Med; 2005 May; 352(19):1977-84. PubMed ID: 15888698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should patients with a pre-operative prostate-specific antigen greater than 15 ng/ml be offered radical prostatectomy?
    O'Brien MF; Connolly SS; Kelly DG; O'Brien A; Quinlan DM; Mulvin DW
    Ir J Med Sci; 2004; 173(1):23-6. PubMed ID: 15732232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extraperitoneal standard laparoscopic radical prostatectomy.
    Rozet F; Arroyo C; Cathelineau X; Barret E; Prapotnich D; Vallancien G
    J Endourol; 2004 Sep; 18(7):605-9; discussion 609-10. PubMed ID: 15597645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.
    D'Amico AV; Renshaw AA; Cote K; Hurwitz M; Beard C; Loffredo M; Chen MH
    J Clin Oncol; 2004 Sep; 22(18):3726-32. PubMed ID: 15365069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer.
    Diblasio CJ; Kattan MW
    Urology; 2003 Dec; 62 Suppl 1():9-18. PubMed ID: 14747038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy.
    Brandli DW; Koch MO; Foster RS; Bihrle R; Gardner TA
    BJU Int; 2003 Jul; 92(1):19-22; discussion 22-3. PubMed ID: 12823376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.
    Vanasupa BP; Paquette EL; Wu H; Sun L; McLeod DG; Moul JW
    Urol Oncol; 2002; 7(4):167-72. PubMed ID: 12474533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.